Basiliximab.txt Basiliximab CLINICAL USE Chimeric murine/human monoclonal anti CD25 antibody: Prophylaxis of acute allograft rejection in combination with maintenance immunosuppression DOSE IN NORMAL RENAL FUNCTION 20 mg 2 hours before transplant and 20 mg 4 days after transplant PHARMACOKINETICS Molecular weight                           :Approx 144 000 %Protein binding                           : %Excreted unchanged in urine     : No data Volume of distribution (L/kg)       :4.5–12.7 litres half-life – normal/ESRD (hrs)      :4–10.4 days/Unchanged DOSE IN RENAL IMPAIRMENT GFR (mL/MIN) 20 to 50     : Dose as in normal renal function 10 to 20     : Dose as in normal renal function <10           : Dose as in normal renal function DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES CAPD                :Not dialysed. Dose as in normal renal function HD                     :Not dialysed. Dose as in normal renal functionHDF/high flux   :Unknown dialysability. Dose as in normal renal functionCAV/VVHD      :Not dialysed. Dose as in normal renal function IMPORTANT DRUG INTERACTIONS Potentially hazardous interactions with other drugsCiclosporin: may alter ciclosporin requirementsTacrolimus: may alter tacrolimus requirements ADMINISTRATION ReconstitionReconstitute each vial with 5 mL water for injection then dilute to 50 mL or greater with sodium chloride 0.9% or glucose 5% Route IV infusion Rate of Administration 20–30 minutes Comments– OTHER INFORMATION cinIn vitro studies indicate that basiliximab binds only to activated lymphocytes Basiliximab is detectable in serum for up to 3 months after 15–25 mg doses Use with caution in patients who have previously had basiliximab due to increased risk of developing hypersensitivity reactions. Tags: post-by-auto-php Continue Reading Previous Previous post: Atovaquone.txtNext Next post: Bortezomib.txt Related News sotalol hydrochloride.txt tazocin.txt